Physician profile
You Zhou
NPI 1881261840
$7,257.50
in general payments reported to CMS, 2019-2025
13 companies · $2,953 in 2025
The $2,953 reported for 2025 was more than what 91% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $364 · 2023: $2,558 · 2024: $1,383 · 2025: $2,953.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,126 · Travel and Lodging: $2,768.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,125.92 |
| Travel and Lodging | $2,767.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,486.97 | 2022-2025 | Xen Glaucoma Treatment System |
| Bausch & Lomb Americas INC. | $2,021.51 | 2022-2025 | Envista Mx60 Iol, Crystalens Accommodating Iol (At-52ao), Trulign Iol |
| Alcon Vision LLC | $759.04 | 2022-2025 | Clareon, Hydrus Microstent, Centurion |
| Sight Sciences, INC. | $437.57 | 2022-2025 | Omni Surgical System, Sion Surgical Instrument |
| Horizon Therapeutics Plc | $425.79 | 2023 | Tepezza, Uplizna |
| Sun Pharmaceutical Industries INC. | $278.33 | 2024-2025 | |
| Amgen INC. | $248.38 | 2024 | Tepezza, Uplizna |
| Tarsus Pharmaceuticals, INC. | $210.23 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $121.86 | 2023 | Eylea Hd |
| Glaukos Corporation | $105.56 | 2025 | Idosetr |
| Dompe US, INC. | $99.99 | 2024 | Oxervate |
| Biotissue Holdings INC. | $40.80 | 2024 | |
| Rxsight INC | $21.47 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw You Zhou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.